BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Guaraldi G, Maurice JB, Marzolini C, Monteith K, Milic J, Tsochatzis E, Bhagani S, Morse CG, Price JC, Ingiliz P, Lemoine M, Sebastiani G; SHIVER Network. New Drugs for NASH and HIV Infection: Great Expectations for a Great Need. Hepatology 2020;71:1831-44. [PMID: 32052857 DOI: 10.1002/hep.31177] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Nartey YA, Zhou K, Kim M, Falade-nwulia O, Tucker JD. HIV: hepatic manifestations of HIV and antiretroviral therapy. Comprehensive Guide to Hepatitis Advances 2023. [DOI: 10.1016/b978-0-323-98368-6.00006-9] [Reference Citation Analysis]
2 Shan L, Wang F, Zhai D, Meng X, Liu J, Lv X. New Drugs for Hepatic Fibrosis. Front Pharmacol 2022;13:874408. [DOI: 10.3389/fphar.2022.874408] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Sebastiani G, Milic J, Cervo A, Saeed S, Krahn T, Kablawi D, Al Hinai AS, Lebouché B, Wong P, Deschenes M, Gioè C, Cascio A, Mazzola G, Guaraldi G. Two-Tier Care Pathways for Liver Fibrosis Associated to Non-Alcoholic Fatty Liver Disease in HIV Mono-Infected Patients. JPM 2022;12:282. [DOI: 10.3390/jpm12020282] [Reference Citation Analysis]
4 Franco S, Buccione D, Tural C, Martinez MA. Circulating microRNA signatures that predict liver fibrosis progression in patients with HIV-1/hepatitis C virus coinfections. AIDS 2021;35:1355-63. [PMID: 33813557 DOI: 10.1097/QAD.0000000000002895] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
5 Boeckmans J, Rombaut M, Demuyser T, Declerck B, Piérard D, Rogiers V, De Kock J, Waumans L, Magerman K, Cartuyvels R, Rummens JL, Rodrigues RM, Vanhaecke T. Infections at the nexus of metabolic-associated fatty liver disease. Arch Toxicol 2021;95:2235-53. [PMID: 34027561 DOI: 10.1007/s00204-021-03069-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
6 Fourman LT, Stanley TL, Grinspoon SK. Reply to Maurice and Lemoine. Clin Infect Dis 2021;72:909. [PMID: 32562485 DOI: 10.1093/cid/ciaa796] [Reference Citation Analysis]
7 Maurice JB, Lemoine M. Are Separate Clinical Trials Still Required in Nonalcoholic Steatohepatitis for Patients With and Without Human Immunodeficiency Virus (HIV)? Clin Infect Dis 2021;72:908-9. [PMID: 32562488 DOI: 10.1093/cid/ciaa795] [Reference Citation Analysis]
8 Cervo A, Shengir M, Patel K, Sebastiani G. NASH in HIV. Curr HIV/AIDS Rep 2020;17:601-14. [PMID: 32984925 DOI: 10.1007/s11904-020-00531-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
9 Odagiri N, Matsubara T, Sato-Matsubara M, Fujii H, Enomoto M, Kawada N. Anti-fibrotic treatments for chronic liver diseases: The present and the future. Clin Mol Hepatol 2021;27:413-24. [PMID: 33317250 DOI: 10.3350/cmh.2020.0187] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]